
Cytocure Medicare Private Limited
Establishes and manages healthcare facilities, including labs, diagnostic centers, and pharmacies.
Establishes and manages healthcare facilities, including labs, diagnostic centers, and pharmacies.
Cytocure Medicare Private Limited (CMPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 January 2019 (Six years and four months 1 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹8.34 Cr.
Sanket Mehta, Nilesh Chordiya, Praveen Kammar, and Three other members serve as directors at the Company.
Mumbai, Maharashtra, India
+91-XXXXXXXXXX
U85300MH2019PTC319108
319108
Private Limited Indian Non-Government Company
07 Jan 2019
30 Sep 2024
31 Mar 2024
Unlisted
Roc Mumbai
Name | Designation | Appointment Date | Status |
---|---|---|---|
Praveen Kammar ![]() | Director | 07-Jan-2019 | Current |
Nilesh Chordiya ![]() | Additional Director | 17-Nov-2022 | Current |
Sanket Mehta ![]() | Director | 07-Jan-2019 | Current |
Jay Anam ![]() | Director | 07-Jan-2019 | Current |
Jageshwar Pandey ![]() | Director | 07-Jan-2019 | Current |
Chetan Anchan ![]() | Director | 17-Mar-2020 | Current |
Cytocure Medicare Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 70.43% increase. The company also saw a substantial improvement in profitability, with a 140.13% increase in profit. The company's net worth Soared by an impressive increase of 555.27%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
In 2023, Cytocure Medicare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Sanket Mehta, Nilesh Chordiya and 4 more are mutual person
Sanket Mehta, Nilesh Chordiya and 4 more are mutual person
Sanket Mehta and Jay Anam are mutual person
Sanket Mehta, Nilesh Chordiya and 3 more are mutual person
Praveen Kammar and Jay Anam are mutual person
₹83.42 M
₹0
Date | Lender | Amount | Status |
---|---|---|---|
29 Nov 2023 | Others | ₹2.76 Cr | Open |
28 Dec 2022 | Others | ₹3.22 M | Open |
30 Sep 2021 | Others | ₹2.00 Cr | Open |
29 May 2021 | Yes Bank Limited | ₹3.35 M | Open |
16 Dec 2020 | Others | ₹2.05 Cr | Open |
Cytocure Medicare has a workforce of 28 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Cytocure Medicare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cytocure Medicare's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
A charge with Others of Rs. 27.64 M registered on 29 Nov 2023 with Charge ID 100825235 was modified on 09 Jan 2025.
Cytocure Medicare Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Cytocure Medicare Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai.
A charge with Others amounted to Rs. 27.64 M with Charge ID 100825235 was registered on 29 Nov 2023.
A charge with Others of Rs. 20.50 M registered on 16 Dec 2020 with Charge ID 100402236 was modified on 24 Apr 2023.
A charge with Others amounted to Rs. 3.22 M with Charge ID 100668097 was registered on 28 Dec 2022.
Cytocure Medicare Private Limited was incorporated on 07 Jan 2019.
The authorized share capital of Cytocure Medicare Private Limited is ₹ 0.10 M and paid-up capital is ₹ 0.10 M.
Currently 6 directors are associated with Cytocure Medicare Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Cytocure Medicare Private Limited is 6Th Floor 601 602 Plot No.501 F3 Silver Point Lbs Marg New Maneklal Estate, Ghatkopar West India, Mumbai, Maharashtra, 400086.
The corporate identification number (CIN) of Cytocure Medicare Private Limited is U85300MH2019PTC319108 and the company number is 319108 as per Ministry of Corporate Affairs (MCA).
According to the financial reports for the fiscal year 2023, the revenue trend for Cytocure Medicare Private Limited has risen by 70.43%.
As Per 2023 financial reports, 28 employees are currently employed by Cytocure Medicare Private Limited.
The financial reports for the fiscal year 2023 indicates that The net worth of Cytocure Medicare Private Limited has experienced an upsurge of 555.27%.
As per the financial statements for fiscal Year 2023, The total open charges for Cytocure Medicare Private Limited amount to ₹ 8.34 Cr.
The most recent Balance Sheet for Cytocure Medicare Private Limited was filed with the ROC on 31 Mar 2024.
Search company & director profiles for free and gain access to critical business data.